vs

Side-by-side financial comparison of BLACKBERRY Ltd (BB) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

Orthofix Medical Inc. is the larger business by last-quarter revenue ($219.9M vs $141.8M, roughly 1.6× BLACKBERRY Ltd). BLACKBERRY Ltd runs the higher net margin — 9.7% vs -1.0%, a 10.7% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -0.8%). BLACKBERRY Ltd produced more free cash flow last quarter ($17.4M vs $16.8M). Over the past eight quarters, BLACKBERRY Ltd's revenue compounded faster (17.8% CAGR vs 8.0%).

BlackBerry Limited, formerly Research In Motion (RIM), is a Canadian software company specializing in secure communications and the Internet of Things (IoT). Founded in 1984, it developed the BlackBerry brand of two-way pagers, smartphones, and tablets. The company later transitioned to providing software and services and holds critical software application patents.

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

BB vs OFIX — Head-to-Head

Bigger by revenue
OFIX
OFIX
1.6× larger
OFIX
$219.9M
$141.8M
BB
Growing faster (revenue YoY)
OFIX
OFIX
+2.8% gap
OFIX
2.0%
-0.8%
BB
Higher net margin
BB
BB
10.7% more per $
BB
9.7%
-1.0%
OFIX
More free cash flow
BB
BB
$580.0K more FCF
BB
$17.4M
$16.8M
OFIX
Faster 2-yr revenue CAGR
BB
BB
Annualised
BB
17.8%
8.0%
OFIX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
BB
BB
OFIX
OFIX
Revenue
$141.8M
$219.9M
Net Profit
$13.7M
$-2.2M
Gross Margin
77.5%
71.1%
Operating Margin
8.4%
0.2%
Net Margin
9.7%
-1.0%
Revenue YoY
-0.8%
2.0%
Net Profit YoY
224.5%
92.4%
EPS (diluted)
$0.02
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BB
BB
OFIX
OFIX
Q4 25
$141.8M
$219.9M
Q3 25
$129.6M
$205.6M
Q2 25
$121.7M
$203.1M
Q1 25
$141.7M
$193.6M
Q4 24
$143.6M
$215.7M
Q3 24
$126.2M
$196.6M
Q2 24
$123.4M
$198.6M
Q1 24
$102.1M
$188.6M
Net Profit
BB
BB
OFIX
OFIX
Q4 25
$13.7M
$-2.2M
Q3 25
$13.3M
$-22.8M
Q2 25
$1.9M
$-14.1M
Q1 25
$-7.4M
$-53.1M
Q4 24
$-10.5M
$-29.1M
Q3 24
$-19.7M
$-27.4M
Q2 24
$-41.4M
$-33.4M
Q1 24
$-56.2M
$-36.0M
Gross Margin
BB
BB
OFIX
OFIX
Q4 25
77.5%
71.1%
Q3 25
74.5%
72.2%
Q2 25
74.2%
68.7%
Q1 25
73.5%
62.8%
Q4 24
78.1%
69.0%
Q3 24
70.2%
68.7%
Q2 24
72.9%
67.8%
Q1 24
67.5%
Operating Margin
BB
BB
OFIX
OFIX
Q4 25
8.4%
0.2%
Q3 25
8.9%
-8.3%
Q2 25
1.6%
-7.9%
Q1 25
-5.6%
-25.2%
Q4 24
13.6%
-5.3%
Q3 24
1.7%
-9.6%
Q2 24
-10.5%
-12.5%
Q1 24
50.0%
-15.6%
Net Margin
BB
BB
OFIX
OFIX
Q4 25
9.7%
-1.0%
Q3 25
10.3%
-11.1%
Q2 25
1.6%
-6.9%
Q1 25
-5.2%
-27.4%
Q4 24
-7.3%
-13.5%
Q3 24
-15.6%
-13.9%
Q2 24
-33.5%
-16.8%
Q1 24
-55.0%
-19.1%
EPS (diluted)
BB
BB
OFIX
OFIX
Q4 25
$0.02
$-0.05
Q3 25
$0.02
$-0.57
Q2 25
$0.00
$-0.36
Q1 25
$-0.01
$-1.35
Q4 24
$-0.02
$-0.76
Q3 24
$-0.03
$-0.71
Q2 24
$-0.07
$-0.88
Q1 24
$-0.08
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BB
BB
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$304.2M
$82.0M
Total DebtLower is stronger
$196.2M
Stockholders' EquityBook value
$741.1M
$450.0M
Total Assets
$1.2B
$850.6M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BB
BB
OFIX
OFIX
Q4 25
$304.2M
$82.0M
Q3 25
$290.5M
$62.9M
Q2 25
$306.6M
$65.6M
Q1 25
$337.8M
$58.0M
Q4 24
$220.0M
$83.2M
Q3 24
$211.0M
$30.1M
Q2 24
$229.0M
$26.4M
Q1 24
$237.1M
$27.0M
Total Debt
BB
BB
OFIX
OFIX
Q4 25
$196.2M
Q3 25
$195.9M
$157.2M
Q2 25
$195.6M
$157.0M
Q1 25
$195.3M
$156.9M
Q4 24
$157.0M
Q3 24
$118.5M
Q2 24
$118.0M
Q1 24
$194.1M
$118.2M
Stockholders' Equity
BB
BB
OFIX
OFIX
Q4 25
$741.1M
$450.0M
Q3 25
$725.1M
$442.5M
Q2 25
$725.1M
$458.3M
Q1 25
$719.9M
$458.3M
Q4 24
$725.2M
$503.1M
Q3 24
$732.1M
$525.9M
Q2 24
$742.6M
$546.0M
Q1 24
$775.1M
$570.3M
Total Assets
BB
BB
OFIX
OFIX
Q4 25
$1.2B
$850.6M
Q3 25
$1.2B
$832.6M
Q2 25
$1.2B
$837.2M
Q1 25
$1.3B
$823.1M
Q4 24
$1.3B
$893.3M
Q3 24
$1.3B
$867.9M
Q2 24
$1.3B
$882.0M
Q1 24
$1.4B
$906.0M
Debt / Equity
BB
BB
OFIX
OFIX
Q4 25
0.26×
Q3 25
0.27×
0.36×
Q2 25
0.27×
0.34×
Q1 25
0.27×
0.34×
Q4 24
0.31×
Q3 24
0.23×
Q2 24
0.22×
Q1 24
0.25×
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BB
BB
OFIX
OFIX
Operating Cash FlowLast quarter
$18.3M
$27.7M
Free Cash FlowOCF − Capex
$17.4M
$16.8M
FCF MarginFCF / Revenue
12.3%
7.6%
Capex IntensityCapex / Revenue
0.6%
4.9%
Cash ConversionOCF / Net Profit
1.34×
TTM Free Cash FlowTrailing 4 quarters
$42.8M
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BB
BB
OFIX
OFIX
Q4 25
$18.3M
$27.7M
Q3 25
$3.9M
$12.4M
Q2 25
$-18.0M
$11.6M
Q1 25
$41.6M
$-18.4M
Q4 24
$6.0M
$23.7M
Q3 24
$-16.0M
$11.7M
Q2 24
$-15.1M
$9.0M
Q1 24
$-15.5M
$-18.6M
Free Cash Flow
BB
BB
OFIX
OFIX
Q4 25
$17.4M
$16.8M
Q3 25
$3.1M
$2.5M
Q2 25
$-18.9M
$4.5M
Q1 25
$41.2M
$-25.1M
Q4 24
$5.2M
$15.2M
Q3 24
$-16.5M
$6.3M
Q2 24
$-16.5M
$-360.0K
Q1 24
$-17.6M
$-29.1M
FCF Margin
BB
BB
OFIX
OFIX
Q4 25
12.3%
7.6%
Q3 25
2.4%
1.2%
Q2 25
-15.5%
2.2%
Q1 25
29.1%
-13.0%
Q4 24
3.6%
7.0%
Q3 24
-13.1%
3.2%
Q2 24
-13.4%
-0.2%
Q1 24
-17.2%
-15.4%
Capex Intensity
BB
BB
OFIX
OFIX
Q4 25
0.6%
4.9%
Q3 25
0.6%
4.8%
Q2 25
0.7%
3.5%
Q1 25
0.3%
3.5%
Q4 24
0.6%
4.0%
Q3 24
0.4%
2.7%
Q2 24
1.1%
4.7%
Q1 24
2.1%
5.6%
Cash Conversion
BB
BB
OFIX
OFIX
Q4 25
1.34×
Q3 25
0.29×
Q2 25
-9.47×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BB
BB

QNX$68.7M48%
Secure Communication$67.0M47%
Licensing$6.1M4%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons